QUALITY ASSURANCE AND DEVELOPMENT OF STANDARDS
8. QUALITY ASSURANCE AND DEVELOPMENT OF STANDARDS
Practice guideline programmes, are one of many types of quality programme, which are increasingly being used to improve the quality of care (Ovretveit and Gustafson, 2003). One of the key components of a guideline programme is identification of or setting of key standards and criteria for audit. These clini- cal standards, based on existing evidence, would be used subsequently as the criterion for evaluating the quality of care provided by an organisation or indi- vidual unit or department. Such quality assurance may be undertaken through an internal or external peer review or through an accreditation process (Del Mar, 2001; Steel, 2001). In the United Kingdom, as in Australia, guidelines and clinical standards underpin much of the quality, or more recently, the clinical governance agenda (Scally and Donaldson, 1998). This process aims to make it a statutory responsibility for each organisation to be accountable for ensuring the monitoring and improvement of the quality of healthcare it provides (Scally and Donaldson, 1998).
Clinical standards primarily enable identification of the essentials that need to be right in the treatment of particular conditions if outcomes for the patients are to be optimised. Standards can be set at several levels: minimal, normative, and exemplary or may be deemed essential or desirable (Del Mar, 2001). It is important to recognise which level should be applied to any stan- dard as minimal standards are primarily aimed at promoting basic levels of care by identifying those areas or professionals who perhaps require remedial, or in rare cases even punitive action. Outcome-related standards are deemed as the “gold standard” of performance measurement but in reality they are diffi- cult to capture, particularly in the short term (Davies and Crombie, 1997; Goddard et al., 2002). Increasingly, process or to a lesser extent structure mea- sures are deemed more attractive especially if they are linked through evidence to outcomes (Crombie and Davies, 1998). Indeed, guidelines or care pathways will outline intervention or processes of care that lead to a desired outcome (Nathwani et al., 2001). The timely (within 4–8 hr of admission) administra- tion of appropriate intravenous antibiotics for patients with severe CAP is
30 Dilip Nathwani regarded as a key quality indicator (Nathwani et al., 2001, 2002). This inter-
vention is regarded as an important, validated, credible, consistent, simple, and measurable process standard based on evidence that is valued by clinicians, quality administrators, and patients (Nathwani et al., 2002). A CAP audit in Tayside used this as one of the key performance indicators in prospectively evaluating pneumonia care. This study revealed that a significant 39% of patients admitted with severe CAP did not receive antibiotics within the appro- priate timeframe. Indeed, 29% did not receive intravenous antibiotics within
24 hr of hospital admission (Marrie et al., 2000). Poor performance on a process measure gives a clear indication of the remedial action that is required and this can be linked to an incentive to bring about positive change. This audit in Dundee stimulated broad educational feedback and the development and implementation of a care pathway for CAP (Marrie et al., 2000) which will be subject to further evaluation (G. Barlow, personal communication). The path- way implementation is supported by a number of proactive educational and feedback interventions. On the other hand, a commonly used crude outcome marker of death is more difficult to interpret as it is insensitive to the quality of healthcare received and can be influenced by a range of other factors (Mant and Hicks, 1995). In our CAP audit (Nathwani et al., 2002), compliance with the unit protocol did appear to correlate to a reduction in mortality but the association was by no means robust.
Parts
» Antibiotic Policies: Theory and Practice
» THEORIES OF FACILITATING CHANGE
» OTHER APPROACHES TO GUIDELINE DEVELOPMENT
» QUALITY ASSURANCE AND DEVELOPMENT OF STANDARDS
» DEVELOPMENT OF CLINICAL STANDARDS IN SCOTLAND
» WHICH QI INTERVENTIONS HAVE BEEN STUDIED IN CAP?
» LINKING PROCESS OF CARE TO OUTCOMES IN QI
» WHAT IS THE EVIDENCE THAT QI INITIATIVES IMPROVE PROCESS OF CARE IN CAP?
» WHAT IS THE EVIDENCE THAT QI INITIATIVES IMPROVE OUTCOMES IN CAP?
» Designing and implementing a CAP intervention
» LEVEL OF AGGREGATION OF ANTIMICROBIALS
» ANTIMICROBIAL USAGE MEASURES
» Relationships based on patient-specific data
» Relationships based on aggregate usage
» ANTIBIOTIC CONSUMPTION; ALTERNATIVE UNITS OF MEASUREMENT
» ANTIBIOTIC CONSUMPTION CALCULATOR
» BENCHMARKING FOR REDUCING VANCOMYCIN USE AND VANCOMYCIN- RESISTANT ENTEROCOCCI IN US ICU S
» THE HARVARD EMERGENCY DEPARTMENT QUALITY STUDY
» ANALYSIS BY INDIVIDUAL ANTIMICROBIAL AGENT
» BENCHMARKING WITH OTHER ANTIMICROBIAL UTILISATION DATA
» STATE OF THE ART OF ANTIBIOTIC PROPHYLAXIS IN SURGERY
» AUDITING AND IMPROVING THE QUALITY OF ANTIBIOTIC PROPHYLAXIS IN SURGERY
» TYPES OF STUDIES TO OBTAIN QUALITY DATA ON A PATIENT LEVEL
» MULTIDISCIPLINARY ANTIMICROBIAL MANAGEMENT TEAMS
» THE ROLE OF THE PHARMACIST IN INFECTION MANAGEMENT
» TRAINING AND SUPPORT IN INFECTION MANAGEMENT FOR PHARMACISTS
» ANTIBIOTIC POLICY IN THE TERTIARY CARE CENTRE
» ANTIBIOTIC CONSUMPTION IN ICU S
» ANTIBIOTIC RESISTANCE IN ICU
» The impact of antibiotic policies and antibiotic consumption on antibiotic resistance
» IT and benchmarking to improve antibiotic prescribing
» COST OF HOSPITAL-ACQUIRED INFECTION
» THE COST OF ANTIMICROBIAL RESISTANCE
» Costs of screening/surveillance cultures
» Isolation, cohorting, and contact isolation
» EPIDEMIOLOGY OF INVASIVE FUNGAL INFECTIONS
» Antifungal resistance in Candida species
» Antifungal resistance cannot be transmitted by extrachromosomal DNA
» RATIONAL USE OF ANTIFUNGAL AGENTS
» THE CHANGING FACE OF VIRAL INFECTIONS AND THEIR MANAGEMENT
» PROBLEMS ASSOCIATED WITH ANTIVIRAL THERAPY
» ANTIVIRAL TREATMENT STRATEGIES
» ANTIVIRAL PROPHYLAXIS STRATEGIES
» ANTIBIOTIC CONCENTRATIONS AT TARGET SITES
» An infant with aplastic anaemia
» A long-standing E. coli infection of liver cysts
» BREAKPOINTS: A SHORT HISTORY AND OVERVIEW
» PHARMACODYNAMIC RELATIONSHIPS AND EMERGENCE OF RESISTANCE
» EVALUATION OF THE ANTIMICROBIAL RESISTANCE SURVEILLANCE DATA PUBLISHED IN THE MEDICAL LITERATURE
» PRACTICAL ASPECTS OF THE IMPLEMENTATION OF THE SURVEILLANCE PROGRAM
» Multivariate analysis methods
» Evolutionary genetic approaches
» Study of the relationship between bacterial resistance and antimicrobial consumption
» To predict the short-term evolution of resistance
» To evaluate interventions to control antibiotic resistance
» DISINFECTANTS: TYPES, ACTIONS, AND USAGES
» Evidence of bacterial resistance to biocides
» Mechanisms of bacterial resistance to biocides
» EVIDENCE OF CROSS-RESISTANCE BETWEEN BIOCIDES AND ANTIBIOTICS
» DISINFECTANT USAGE AND ANTIBIOTIC RESISTANCE
» METHODS OF LITERATURE REVIEW
» PROBLEMS WITH INTERPRETATION OF PUBLISHED STUDIES
» Distribution of educational materials
» Audit and feedback with or without other educational materials
» Educational group meetings or seminars
» Educational outreach/academic detailing
» Financial/healthcare system changes
» EFFECT OF INTERVENTIONS ON ANTIBIOTIC RESISTANCE
» DDD/1,000 INHABITANTS AND DAY (DID)
» PRESCRIPTIONS/1,000 INHABITANTS AND YEAR
» INDICATIONS FOR ANTIBIOTIC PRESCRIPTIONS
» POSSIBLE CAUSES FOR OBSERVED VARIATIONS IN ANTIBIOTIC USE
» DETERMINANTS OF ANTIBIOTIC CONSUMPTION
» COLLECTIVE AWAKENING AND PROGRESSIVE MOBILIZATION OF FRENCH PUBLIC HEALTH AUTHORITIES
» ANTIBIOTIC USE AND COST TRENDS
» IMPACT ON HEALTH BUDGETS OF ANTIBIOTIC USE
» ACCESS TO ESSENTIAL ANTIBIOTICS AT ALL LEVELS OF CARE
» EPIDEMIOLOGY OF ANTIMICROBIAL RESISTANCE
» THREAT OF ANTIMICROBIAL RESISTANCE
» ECONOMIC IMPLICATIONS OF ANTIMICROBIAL RESISTANCE
» FACTORS CONTRIBUTING TO DEVELOPMENT AND SPREAD OF RESISTANCE
» STRATEGIES FOR CONTAINMENT OF RESISTANCE IN DEVELOPING COUNTRIES
» Antibacterial resistance and policies
» Policies, guidelines, and education on antibacterial use
» Discovery, development, and commercialization in the face of policies
» Antibacterial development, labelling, and benefits
» WHAT CAN BE DONE NOW ABOUT ANTIBIOTIC RESISTANCE?
» HOW CAN THE DIAGNOSTIC LABORATORY HELP?
Show more